ClinicalTrials.govpublic full text
High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2
kidney cancer, recurrent renal cell cancer, stage iv renal cell cancer, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 810391
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.